In a report released today, Luca Issi from RBC Capital maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report), with a ...

The shares were sold at a price of $21 each, totaling $20,139. Following this transaction, Olukotun holds 35,781 shares ...

A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...

Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Milestone Pharmaceuticals (MIST – Research Report) and keeping the ...

Some Kansas City Chiefs fans have waited since Saturday afternoon to enter Arrowhead Stadium.

HC Wainwright reaffirmed their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a research ...

Stock analysts at Leerink Partnrs reduced their Q3 2025 earnings per share estimates for Arrowhead Pharmaceuticals in a ...

Arrowhead Pharmaceuticals Inc (ARWR) stock saw a decline, ending the day at $20.76 which represents a decrease of $-0.77 or -3.58% from the prior close of $21.53. The stock opened at $21.23 and ...

Arrowhead Pharmaceuticals Inc (ARWR) stock saw a modest uptick, ending the day at $21.53 which represents a slight increase of $1.82 or 9.23% from the prior close of $19.71. The stock opened at $20.05 ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), a biopharmaceutical company with a market capitalization of $2.68 billion ...